ClinicalTrials.gg
TerminatedNCT05552859TRENTUpdated Sep 8, 2025Results posted

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

A Phase 4 interventional study of Insulin glargine 300 U/mL and Insulin degludec 100 U/mL in Type 2 Diabetes Mellitus and Renal Impairment, sponsored by Sanofi. Terminated at 68 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Why this study was terminated
Sponsor decision to cancel trial due to poor recruitment/ severe recruitment delay and not related to safety concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
139th of 175
62 · median 253
Started
2022
with 6 others
Phase 4
103 of 176
2 open now
Registered
166th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 139th largest by enrollment of the 175 interventional ones that give a count, is one of 7 that started in 2022, is one of 103 in phase 4, and was the 166th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The TRENT trial is designed to confirm the efficacy and safety of Gla-300 compared with IDeg-100 in insulin-naïve patient (participants who have not tried insulin) with Type 2 Diabetes Mellitus (T2DM) and renal impairment. It will test the hypothesis that Gla-300 is non-inferior to IDeg-100 with glucose control. If achieved, the trial will also test for the superiority of Gla-300 compared with IDeg-100 in Hemoglobin A1c (HbA1c) reduction, without an increased potential risk of hypoglycemia.

Read the detailed description

The trial will consist of the following periods:

  • A screening period of up to 2 weeks,
  • A 24-week, open-label treatment period, including a titration period and a maintenance period.
  • A 7-day, post-treatment, safety follow-up period after the last dose of the study drug or after premature/permanent discontinuation from study drug treatment. This will be a phone contact, but could be a site visit if ongoing or new AEs emerge during the post-treatment period, if necessary.
03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Renal Impairment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is an adult aged ≥18 years at screening.
  2. Was diagnosed with Type 2 Diabetes Mellitus (T2DM) of >1-year duration and had glycemic levels above target with OADs (Oral Antidiabetic Drug) with or without GLP-1 RA (glucagon-like peptide-1 receptor agonist) (oral or injectable) at stable doses for ≥3 months before the screening period.
  3. Has an ≥7.5% and ≤10.5% at screening.
  4. Has renal impairment, as defined by an (estimated glomerular filtration rate) of \<60 mL/min/1.73m2 and ≥15 mL/min/1.73m2.
  5. Has adequately controlled blood pressure with stable antihypertensive therapy at trial inclusion.
  6. Is insulin-naïve, except for short use of insulin not exceeding 15 days during the last year before the screening period.
  7. Is capable of understanding the written , and provides signed written informed consent.
  8. Is willing and able to complete the electronic diary (eDiary) and agrees to comply with protocol requirements.
  9. Is willing and able to fast without having administered study drug for scheduled site visits.

Exclusion criteria

Exclusion Criteria:

  1. Has initiated treatment with potential novel therapies like dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA.
  2. Has a (BMI)* >45 kg/m² during the screening period.
  3. Has a history of hypoglycemia unawareness (defined as the onset of neuroglycopenia before the appearance of autonomic warning symptoms [eg, blurred vision, difficulty speaking, feeling faint, difficulty thinking, and confusion] or as the failure to sense a significant fall in blood glucose below normal levels).
  4. Has a history of 2 or more episodes of severe hypoglycemia and/or 2 or more episodes of diabetic ketoacidosis within the 6 months before the day of screening.
  5. Has been exposed to other drug(s) within 1 month or 5 half-lives from screening, whichever is longer.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Gla-300 arm

    Gla-300 will be administered once daily for 24 weeks

    Drug: Insulin glargine 300 U/mL

  • Active comparator
    IDeg-100 arm

    Ideg-100 will be administered once daily for 24 weeks

    Drug: Insulin degludec 100 U/mL

Interventions

  • DrugInsulin glargine 300 U/mL

    Drug page: Insulin Glargine

    Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.

    Also known as: Toujeo, HOE901-U300

  • DrugInsulin degludec 100 U/mL

    Drug page: Insulin degludec

    Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.

    Also known as: Tresiba

06

What researchers measure

Primary outcomes

  1. Difference in the Mean Change From Baseline to Week 24 in HbA1c Level (Gla-300 vs IDeg-100)

    Change in HbA1c was calculated by subtracting baseline value from Week 24 value and then mean values were calculated.

    Time frame: Baseline to 24 weeks

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24

    Change in FPG was calculated by subtracting baseline value from the Week 24 value.

    Time frame: Baseline to 24 weeks

  2. Change in Fasting Self-Measured Plasma Glucose (SMPG) From Baseline to Week 24

    Change in SMPG was calculated by subtracting baseline value from the Week 24 value.

    Time frame: Baseline to 24 weeks

  3. Change in 7-point SMPG Profiles From Baseline to Week 24, Per Time Point Within 24-hour Period

    7-point SMPG profiles were measured at the following 7 points: pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.

    Time frame: Baseline to 24 weeks

  4. Percentage of Participants Reaching HbA1c Target of <7.0% at Week 24

    If a patient has a missing HbA1c value at Week 24, it is assumed that they did not reach the HbA1c target of \<7.0%. HbA1c value of 7.0% is equivalent to 53.0 mmol/mol.

    Time frame: At week 24

  5. Percentage of Participants With ≥1 Episode(s) of Confirmed Hypoglycemia Event (Cut-off Value 70 mg/dL and 54 mg/dL) During the 24-week Treatment Period.

    Any event recorded with Yes as response to the question, "Was a glucose measurement obtained at the time of the event before countermeasure?" and a measurable glucose level of \<70 mg/dL. ADA (American Diabetes Association), Level 1 was defined as a measurable glucose concentration of \<70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L).

    Time frame: Baseline to end of study (25 weeks)

  6. Rate of Hypoglycemia Per Participant-year

    Computed as: 365.25/12 × (number of episodes of hypoglycemia)/(number of days exposed in time window)

    Time frame: Baseline to end of study (25 weeks)]

  7. Percentage of Participants and Event Rate of Hypoglycemia by Trial Period (for ≤12 Weeks, for >13 Weeks to ≤24 Weeks)

    Hypoglycemic events measured at the following intervals: Weeks 1-12 and Weeks 13-24.

    Time frame: Baseline to end of study (25 weeks)

  8. The 24-hour (All Time), Occurrence of Each Episode of Documented Hypoglycemia by Category, Presented by 2-hour Timeframe Over 24 Hours During the 24-week Treatment Period.

    The time range for this outcome measure was 00:00 to 05:59, both inclusive. Hypoglycemia Categories \[(symptomatic, asymptomatic, severe) are defined per the American Diabetes Association/European Association for the Study of Diabetes hypoglycemia Classification\]

    Time frame: Baseline to end of study (25 weeks)

  9. Number of Participants With Adverse Events (AEs)) and Serious Adverse Events (SAEs), Including Adverse Events of Special Interest (AESIs)

    Adverse events (AEs) and serious adverse events (SAEs), including adverse events of special interest (AESIs), and other safety evaluations, including vital signs and body weight.

    Time frame: Baseline to end of study (25 weeks)

07

Results

Posted Sep 5, 2024
Limitations and caveats
The sponsor made the strategic decision to discontinue the trial due to a significant recruitment delay (ie, the number of randomized participants remained significantly lower \[\<10% than originally planned sample size\]). No safety signals were detected during the trial, and the trial team remained blinded to the data collected for the randomized participants at the time of early discontinuation of the trial.

Participant flow

The study was conducted at 68 study centers across 5 countries. A total of 182 participants were screened between 05 December 2022 and 30 June 2023, of whom 120 were screen failures. The number of randomized participants remained significantly lower (\<10%) than was originally planned. Consequently, the estimated results would have been delayed by several years. Hence, the sponsor made the strategic decision to discontinue the trial due to this significant recruitment delay, not related safety.

Participant flow — Overall Study
MilestoneGla-300 U/mL ArmIDeg-100 U/mL Arm
Started3131
Completed11
Not completed3030
Withdrew: Study was terminated by the sponsor due to poor recruitment/severe recruitment delay3030

Outcome measures

PrimaryDifference in the Mean Change From Baseline to Week 24 in HbA1c Level (Gla-300 vs IDeg-100)

Change in HbA1c was calculated by subtracting baseline value from Week 24 value and then mean values were calculated.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · percentage of HbA1c
Difference in the Mean Change From Baseline to Week 24 in HbA1c Level (Gla-300 vs IDeg-100)
percentage of HbA1cGla-300 U/mL ArmIDeg-100 U/mL Arm
Difference in the Mean Change From Baseline to Week 24 in HbA1c Level (Gla-300 vs IDeg-100)-0.4 ± 1.73-1.0 ± 0.98
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Week 24

Change in FPG was calculated by subtracting baseline value from the Week 24 value.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · (mg/dL)
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24
(mg/dL)Gla-300 U/mL ArmIDeg-100 U/mL Arm
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24-36.4 ± 25.16-55.5 ± 22.67
SecondaryChange in Fasting Self-Measured Plasma Glucose (SMPG) From Baseline to Week 24

Change in SMPG was calculated by subtracting baseline value from the Week 24 value.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · (mmol/L)
Change in Fasting Self-Measured Plasma Glucose (SMPG) From Baseline to Week 24
(mmol/L)Gla-300 U/mL ArmIDeg-100 U/mL Arm
Change in Fasting Self-Measured Plasma Glucose (SMPG) From Baseline to Week 24-4.00—
SecondaryChange in 7-point SMPG Profiles From Baseline to Week 24, Per Time Point Within 24-hour Period

7-point SMPG profiles were measured at the following 7 points: pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.

Time frame:
Baseline to 24 weeks
Reported as:
Mean · (mmol/L)
Change in 7-point SMPG Profiles From Baseline to Week 24, Per Time Point Within 24-hour Period
(mmol/L)Gla-300 U/mL ArmIDeg-100 U/mL Arm
7-Point SMPG Profile (mmol/L), before breakfast (fasting)-4.13—
7-Point SMPG Profile (mmol/L), 2 hours after breakfast-1.30—
7-Point SMPG Profile (mmol/L), before lunch0.31—
7-Point SMPG Profile (mmol/L), 2 hours after lunch0.63—
7-Point SMPG Profile (mmol/L), before dinner2.18—
7-Point SMPG Profile (mmol/L), 2 hours after dinner-5.36—
7-Point SMPG Profile (mmol/L), at bedtime-6.20—
SecondaryPercentage of Participants Reaching HbA1c Target of <7.0% at Week 24

If a patient has a missing HbA1c value at Week 24, it is assumed that they did not reach the HbA1c target of \<7.0%. HbA1c value of 7.0% is equivalent to 53.0 mmol/mol.

Time frame:
At week 24
Reported as:
Count of participants · Participants
Percentage of Participants Reaching HbA1c Target of <7.0% at Week 24
ParticipantsGla-300 U/mL ArmIDeg-100 U/mL Arm
Percentage of Participants Reaching HbA1c Target of <7.0% at Week 2442
SecondaryPercentage of Participants With ≥1 Episode(s) of Confirmed Hypoglycemia Event (Cut-off Value 70 mg/dL and 54 mg/dL) During the 24-week Treatment Period.

Any event recorded with Yes as response to the question, "Was a glucose measurement obtained at the time of the event before countermeasure?" and a measurable glucose level of \<70 mg/dL. ADA (American Diabetes Association), Level 1 was defined as a measurable glucose concentration of \<70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L).

Time frame:
Baseline to end of study (25 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With ≥1 Episode(s) of Confirmed Hypoglycemia Event (Cut-off Value 70 mg/dL and 54 mg/dL) During the 24-week Treatment Period.
percentage of participantsGla-300 U/mL ArmIDeg-100 U/mL Arm
Percentage of Participants With ≥1 Episode(s) of Confirmed Hypoglycemia Event (Cut-off Value 70 mg/dL and 54 mg/dL) During the 24-week Treatment Period.35.529.0
SecondaryRate of Hypoglycemia Per Participant-year

Computed as: 365.25/12 × (number of episodes of hypoglycemia)/(number of days exposed in time window)

Time frame:
Baseline to end of study (25 weeks)]
Reported as:
Number · Rate of hypoglycemia per patient-year
Rate of Hypoglycemia Per Participant-year
Rate of hypoglycemia per patient-yearGla-300 U/mL ArmIDeg-100 U/mL Arm
Rate of Hypoglycemia Per Participant-year9.55.6
SecondaryPercentage of Participants and Event Rate of Hypoglycemia by Trial Period (for ≤12 Weeks, for >13 Weeks to ≤24 Weeks)

Hypoglycemic events measured at the following intervals: Weeks 1-12 and Weeks 13-24.

Time frame:
Baseline to end of study (25 weeks)
Reported as:
Count of participants · Participants
Percentage of Participants and Event Rate of Hypoglycemia by Trial Period (for ≤12 Weeks, for >13 Weeks to ≤24 Weeks)
ParticipantsGla-300 U/mL ArmIDeg-100 U/mL Arm
Titration period (Week 1 to Week 12)97
Maintenance period (Week 13 to Week 24)55
SecondaryThe 24-hour (All Time), Occurrence of Each Episode of Documented Hypoglycemia by Category, Presented by 2-hour Timeframe Over 24 Hours During the 24-week Treatment Period.

The time range for this outcome measure was 00:00 to 05:59, both inclusive. Hypoglycemia Categories \[(symptomatic, asymptomatic, severe) are defined per the American Diabetes Association/European Association for the Study of Diabetes hypoglycemia Classification\]

Time frame:
Baseline to end of study (25 weeks)
Reported as:
Number · Episodes
The 24-hour (All Time), Occurrence of Each Episode of Documented Hypoglycemia by Category, Presented by 2-hour Timeframe Over 24 Hours During the 24-week Treatment Period.
EpisodesGla-300 U/mL ArmIDeg-100 U/mL Arm
The 24-hour (All Time), Occurrence of Each Episode of Documented Hypoglycemia by Category, Presented by 2-hour Timeframe Over 24 Hours During the 24-week Treatment Period.119
SecondaryNumber of Participants With Adverse Events (AEs)) and Serious Adverse Events (SAEs), Including Adverse Events of Special Interest (AESIs)

Adverse events (AEs) and serious adverse events (SAEs), including adverse events of special interest (AESIs), and other safety evaluations, including vital signs and body weight.

Time frame:
Baseline to end of study (25 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)) and Serious Adverse Events (SAEs), Including Adverse Events of Special Interest (AESIs)
ParticipantsGla-300 U/mL ArmIDeg-100 U/mL Arm
Adverse Event (AE)57
Serious Adverse Event13
Adverse Event of Special Interest (AESIs)00
Treatment-Emergent SAEs13

Adverse events

Collected over All AEs (serious or nonserious) will be recorded from the signing of the ICF until the safety follow-up visit, patient's permanent discontinuation from the trial, or loss to follow-up, up to 25 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gla-300 U/mL Arm0/31 (0%)1/31 (3.2%)0/31 (0%)
IDeg-100 U/mL Arm1/31 (3.2%)3/31 (9.7%)5/31 (16.1%)
Most frequent serious events
Most frequent serious events
EventGla-300 U/mL ArmIDeg-100 U/mL Arm
Hypertensive Heart DiseaseCardiac disorders0/311/31
Hypoglycemic EventMetabolism and nutrition disorders0/311/31
Retinal artery occlusionEye disorders0/311/31
Cardiac failure congestiveCardiac disorders0/311/31
Circulatory collapseVascular disorders1/310/31
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/311/31
Most frequent other events
Most frequent other events
EventGla-300 U/mL ArmIDeg-100 U/mL Arm
HypoglycemiaMetabolism and nutrition disorders0/313/31
Upper Respiratory Tract InfectionInfections and infestations0/312/31

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Gla-300 ArmIDeg-100 ArmTotal
<=18 years000
Between 18 and 65 years6612
>=65 years252550
Age, Continuous
Age, Continuous(years)Gla-300 ArmIDeg-100 ArmTotal
Mean71.9 ± 7.571.0 ± 7.771.5 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Gla-300 ArmIDeg-100 ArmTotal
Female161531
Male151631
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Gla-300 ArmIDeg-100 ArmTotal
Hispanic or Latino268
Not Hispanic or Latino292554
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gla-300 ArmIDeg-100 ArmTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American314
White272956
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Gla-300 ArmIDeg-100 ArmTotal
Hungary369
United States7916
Czechia538
Poland12921
Serbia448
Weight (kg)
Weight (kg)(kg)Gla-300 ArmIDeg-100 ArmTotal
Mean89.5 ± 25.3089.5 ± 20.3289.5 ± 22.74
BMI (kg//m²)
BMI (kg//m²)((kg/m²))Gla-300 ArmIDeg-100 ArmTotal
Mean31.6 ± 5.5432.2 ± 6.5631.9 ± 6.03

11 further baseline measures are reported on the registry.

08

Study locations

68 sites
  • Yuma Clinical Trials, LLC Site Number: 8400028
    Yuma, Arizona 85364-7110, United States
  • American Clinical Trials Site Number: 8400014
    Buena Park, California 90620-3800, United States
  • Clearview Medical Research LLC Site Number: 8400021
    Canyon Country, California 91351-4138, United States
  • Torrance Clinical Research Institute Site Number: 8400003
    Lomita, California 90717-2101, United States
  • Center for Endocrinology Diabetes and Metabolic Disorders (CEDMD) - CAR Site Number: 8400026
    Santa Clarita, California 91321-2454, United States
  • San Fernando Valley Health Institute - ClinEdge - PPDS Site Number: 8400023
    Van Nuys, California 91405-3605, United States
  • Chase Medical Research LLC Site Number: 8400007
    Waterbury, Connecticut 06708, United States
  • Innovative Research of West Florida Site Number: 8400016
    Clearwater, Florida 33756-2004, United States
  • Evolution Clinical Trials Site number: 8400034
    Hialeah Gardens, Florida 33016, United States
  • Wellness Research Center Inc - Miami Site Number: 8400010
    Miami, Florida 33135-1601, United States
  • Med Research of Florida, LLC Investigator Site: 8400033
    Miami, Florida 33186, United States
  • Florida Institute For Clinical Research LLC Site Number: 8400004
    Orlando, Florida 32825, United States
  • Emory University Site Number: 8400032
    Atlanta, Georgia 30303, United States
  • Agile Clinical Research Trials, LLC Site Number: 8400001
    Atlanta, Georgia 30328-5532, United States
  • Centricity Research Site Number: 8400006
    Columbus, Georgia 31904, United States
  • Georgia Clinical Research Site Number: 8400009
    Lawrenceville, Georgia 30044-5896, United States
  • Endocrine and Metabolic Consultants Research Center Site Number: 8400031
    Rockville, Maryland 20852, United States
  • Diabetes, Obesity, Cardiovascular Clinical Specialists (DOCS) Site Number: 8400019
    Las Vegas, Nevada 89113-3628, United States
  • Mid Hudson Medical Research PLLC Site Number: 8400024
    New Windsor, New York 12553-7754, United States
  • Lucas Research - Morehead City - HyperCore - PPDS Site Number: 8400008
    Morehead City, North Carolina 28557-3126, United States
  • Advanced Medical Research Site Number: 8400012
    Maumee, Ohio 43537-1863, United States
  • Capital Area Research LLC Site Number: 8400029
    Newport, Pennsylvania 17074, United States
  • Jefferson University Physicians (JUP) Site Number: 8400025
    Philadelphia, Pennsylvania 19107-6810, United States
  • Holston Medical Group PC Site Number: 8400018
    Bristol, Tennessee 37620-7353, United States
  • Frontier Medical Center Site Number: 8400035
    El Paso, Texas 79935-4202, United States
  • Diabetes and Thyroid Center of Fort Worth PLLC Site Number: 8400015
    Fort Worth, Texas 76132-4242, United States
  • Juno Research, LLC Site Number: 8400017
    Houston, Texas 77054, United States
  • Reichman and Associates Site Number: 8400013
    Houston, Texas 77074-1691, United States
  • Texas Institute for Kidney and Endocrine Disorders Site Number: 8400027
    Lufkin, Texas 75904-3163, United States
  • Northeast Clinical Research of San Antonio LLC Site Number: 8400022
    Schertz, Texas 78154-1403, United States
  • Consano Clinical Research Site Number: 8400030
    Shavano Park, Texas 78231, United States
  • David Ramstad Associates Research - IACT - HyperCore - PPDS Site Number: 8400005
    Suffolk, Virginia 23435-3763, United States
  • Diabetologie MUDr. Tomas Edelsberger Site Number: 2030001
    Krnov, Moravian-Silesian Region 794 01, Czechia
  • Agentura Science Pro spol. s.r.o.Site Number: 2030002
    Olomouc, Olomouc Region 779 00, Czechia
  • Institut Klinicke A Experimentalni Mediciny Site Number: 2030006
    Prague, Praha, Hlavní Mesto 140 21, Czechia
  • Diacentrum Brandys n. L. Site Number: 2030004
    Brandýs nad Labem-Stará Boleslav, 250 01, Czechia
  • Diabetologicka, interni a obezitologicka ambulance Site Number: 2030005
    Jílové u Prahy, 254 00, Czechia
  • Fakultni nemocnice Kralovske Vinohrady Site Number: 2030007
    Prague, 100 34, Czechia
  • Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz Site Number: 3480006
    Nyíregyháza, Szabolcs-Szatmár-Bereg 4400, Hungary
  • Markusovszky Egyetemi Oktatókórház Site Number: 3480001
    Szombathely, Vas County 9700, Hungary
  • Csolnoky Ferenc Korhaz Site Number: 3480005
    Balatonfüred, Veszprém megye 8230, Hungary
  • Zala Megyei Szent Rafael Korhaz Site Number: 3480002
    Zalaegerszeg, Zala County 8904, Hungary
  • Magyar Honvédség Egészségügyi Központ Site Number: 3480003
    Budapest, 1134, Hungary
  • Somogy Megyei Kaposi Mór Oktató Kórház Site Number: 3480004
    Kaposvár, 7400, Hungary
  • Centrum Medyczne OMEDICA Site Number: 6160013
    Poznan, Greater Poland Voivodeship 60-111, Poland
  • Zaklad Opieki Medycznej "Sanatio" Sp.z o.o. - Osrodek Leczenia Schorzen Cywilizacyjnych Site Number: 6160016
    Krakow, Lesser Poland Voivodeship 31-548, Poland
  • Regionalna Poradnia Diabetologiczna - Wroclaw Site Number: 6160009
    Wroclaw, Lower Silesian Voivodeship 50-127, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna Medica Site Number: 6160008
    Lublin, Lublin Voivodeship 20-538, Poland
  • KO-MED Centra Kliniczne Sp. z o.o. Site Number: 6160010
    Puławy, Lublin Voivodeship 24-100, Poland
  • KO-MED Centra Kliniczne Sp. z o.o. Site Number: 6160012
    Zamość, Lublin Voivodeship 22-400, Poland
  • Prywatny Gabinet Lekarski Centrum Medyczne Diabetika Dorota Mlodawska-Choluj Site Number: 6160015
    Radom, Masovian Voivodeship 26-610, Poland
  • NBR Polska Site Number: 6160003
    Warsaw, Masovian Voivodeship 00-465, Poland
  • Centralny Szpital Kliniczny MSW Site Number: 6160005
    Warsaw, Masovian Voivodeship 02-507, Poland
  • NZOZ Gdanska Poradnia Cukrzycowa Sp. z o.o. Site Number: 6160014
    Gdansk, Pomeranian Voivodeship 80-858, Poland
  • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Site Number: 6160001
    Częstochowa, Silesian Voivodeship 42-207, Poland
  • Specjalistyczna Praktyka Lekarska Site Number: 6160004
    Lubliniec, Silesian Voivodeship 42-700, Poland
  • ETG Lodz Site Number: 6160018
    Lodz, 90-302, Poland
  • Gabinet Lekarski Malgorzata Saryusz-Wolska Site Number: 6160017
    Lódz, 90-132, Poland
  • Praktyka Lekarska Ewa Krzyzagórska Site Number: 6160014
    Poznan, 61-655, Poland
  • Prywatny Gabinet Lekarski, Centrum Medyczne "Diabetika" Site Number:6160002
    Radom, 26-600, Poland
  • ETG Skierniewice - PPDS Site Number: 6160006
    Skierniewice, Lódzkie, Poland
  • KO-MED Centra Kliniczne Sp. z o.o. Site Number:6160011
    Staszów, Świętokrzyskie Voivodeship 28-200, Poland
  • Clinical Hospital Centar Zvezdara Site Number: 6880001
    Belgrade, 11000, Serbia
  • University Clinical Center of Serbia - PPDS Site Number: 6880003
    Belgrade, 11000, Serbia
  • University Clinical Center of Serbia - PPDS Site Number: 6880004
    Belgrade, 11000, Serbia
  • University Clinical Center Nis Site Number: 6880002
    Niš, 18 000, Serbia
  • University Clinical Center Nis Site Number: 6880005
    Niš, 18 000, Serbia
  • Health Center Zajecar Site Number: 6880006
    Zaječar, 19000, Serbia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jul 2023, 7 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Sep 23, 2022
StartActual
Dec 5, 2022
Primary completionActual
Jul 28, 2023
CompletionActual
Aug 4, 2023
Results first posted
Sep 5, 2024
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05552859
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Dec 5, 2022
Primary completion
Jul 28, 2023
Completion
Aug 4, 2023
Results posted
Sep 5, 2024
Last update
Sep 8, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion